OncologyConsults



Metastatic Melanoma:
Managing Benefit and Risk with the New Systemic Therapies

Provided by the Johns Hopkins University School of Medicine and
the Institute for Johns Hopkins Nursing.

Supported by an educational grant from Merck & Co, Inc.

OVERVIEW
Recent advances in the understanding of the immunology and molecular biology of melanoma have changed the therapeutic landscape of patients with metastatic melanoma. Research has led to the introduction of breakthrough drugs that work by targeting the mitogen-activated protein kinase (MAPK) pathway in melanoma cells, which harbors BRAF mutations (targeted therapy) or turning off normal brakes (CTLA-4, PD-1) in the immune system (checkpoint inhibitors). This new generation of therapies, which has demonstrated improved objective response rates and overall survival in large randomized clinical trials, is the focus of this learning initiative. It will help guide healthcare professionals who treat patients with metastatic melanoma, including oncologists, oncology nurses, and oncology physician assistants. This interactive case activity will provide a thorough a review of the emerging knowledge about the molecular biology and immunology of metastatic melanoma and the new systemic therapies that have been built on that knowledge. It also will discuss the latest clinical evidence supporting the place of these drugs in the melanoma treatment paradigm. In addition we will discuss the unique side effects of these new treatments. Finally, the activity will assist practitioners in developing individualized treatment plans for patients with this often lethal, but now more treatable, cancer.

GOAL
The goal of this activity is to provide oncology healthcare providers with the most up-to-date information on the issues of treating and managing patients with metastatic melanoma.

TARGET AUDIENCE
This activity is designed for oncology healthcare providers (oncologists, oncology nurses, and oncology physician assistants) who care for patients with metastatic melanoma. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • EVALUATE the evidence-based findings regarding the new and emergent systemic therapies for patients with metastatic melanoma.
  • ASSESS the role of immuno- and targeted therapy in the treatment paradigm for patients with metastatic melanoma.
  • IDENTIFY the criteria for recommending specific immunotherapeutic and targeted therapies for patients with metastatic melanoma based on their presentation, laboratory, radiological, and histological findings.
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.

CE INFORMATION
Accreditation Statements — This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statements — The Johns Hopkins University School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category I CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This .5 contact hours of educational activity is provided by the Institute for Johns Hopkins Nursing. Nurses should claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until May 11, 2018.

The estimated time to complete this activity: 30 minutes.

Release date: May 20, 2016    Expiration date: May 20, 2018

FACULTY
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation.

Policy on Faculty and Provider Disclosure
It is the policy of the Institute for Johns Hopkins Nursing to require our continuing nursing education faculty and planning committee members to disclose any financial relationships with companies providing program funding or manufacturers of any commercial products discussed in the educational activity.

The following relationships have been reported for this activity:

Chair and Planner
William Sharfman, MD, FACP

Associate Professor of Oncology and Dermatology
Johns Hopkins University School of Medicine
Director of Cutaneous Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Nurse Planner
Rebecca Barshick, RN, MSN

Nurse Educator
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Nurse Reviewer
Helina Somervell, DNP, CRNP, FNP-BC

Lead Nurse Practitioner
Breast, Endocrine, and Melanoma Surgery
The Institute for Johns Hopkins Nursing
Baltimore, Maryland

Participating Faculty Disclosures
Dr Sharfman reports serving as a consultant for Merck & Co, Inc.

No other faculty have indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

Planner Disclosures
Dr Sharfman reports receiving grants/research support from Merck & Co, Inc and serving as a consultant/advisor for Bristol-Myers Squibb Company.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
No faculty member has indicated that his/her presentation will include information on off-label products.

Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this enduring material are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

"The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only."

For CME questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu.
Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.

ACTIVITY INSTRUCTIONS
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME/CNE post-test and evaluation. All 3 sections must be completed to receive CME/CNE credit. A certificate of participation will be available online immediately following successful completion of the activity.

Pre-Test

Metastatic Melanoma:
Managing Benefit and Risk with the New Systemic Therapies

William Sharfman, MD, FACP

Post-Test

This activity was developed in collaboration with ASiM.


© 2017 - OncologyConsults.com